Cargando…

How to Identify Patients at High Risk of Developing Nasal-Type, Extranodal Nature Killer/T-Cell Lymphoma-Associated Hemophagocytic Syndrome

Nasal-type, extranodal nature killer (NK)/T-cell lymphoma-associated hemophagocytic syndrome (NK/T-LAHS) is a rare and life-threatening disease, requiring investigation of risk stratification. We conducted a retrospective study and proposed nomograms to predict NK/T-LAHS. The discriminative ability...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Na, Jiang, Ming, Wu, Wan-Chun, Wei, Wen-Wen, Zou, Li-Qun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8416502/
https://www.ncbi.nlm.nih.gov/pubmed/34490105
http://dx.doi.org/10.3389/fonc.2021.704962
_version_ 1783748197220352000
author Li, Na
Jiang, Ming
Wu, Wan-Chun
Wei, Wen-Wen
Zou, Li-Qun
author_facet Li, Na
Jiang, Ming
Wu, Wan-Chun
Wei, Wen-Wen
Zou, Li-Qun
author_sort Li, Na
collection PubMed
description Nasal-type, extranodal nature killer (NK)/T-cell lymphoma-associated hemophagocytic syndrome (NK/T-LAHS) is a rare and life-threatening disease, requiring investigation of risk stratification. We conducted a retrospective study and proposed nomograms to predict NK/T-LAHS. The discriminative ability and calibration of the nomograms for prediction were tested using C statistics and calibration plots. We analyzed 533 patients with extranodal NK/T-cell lymphoma (ENKTL), out of which 71 were diagnosed with hemophagocytic syndrome (HPS), with a cumulative incidence of 13.3%. Significant difference for 2-year survival was found between patients with and without HPS (14.7% vs. 77.5%). Analyses showed that Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≥2, B symptoms, and bone marrow (BM) invasion were significantly associated with NK/T-LAHS. We used these data as the basis to establish a nomogram of risk index for ENKTL (RINK). In 335 patients with available data for Epstein-Barr virus DNA (EBV-DNA), we found high viral copies (≥4,450 copies/ml) were correlated with NK/T-LAHS. When these data were added to RINK, we developed another nomogram that included EBV-DNA data (RINK-E). The nomograms displayed good accuracy in predicting NK/T-LAHS with a C-statistics of 0.919 for RINK and a C-statistics of 0.946 for RINK-E, respectively. The calibration chart also showed an excellent consistency between the predicted and observed probabilities. The proposed nomograms provided individualized risk estimate of HPS in patients with ENKTL.
format Online
Article
Text
id pubmed-8416502
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-84165022021-09-05 How to Identify Patients at High Risk of Developing Nasal-Type, Extranodal Nature Killer/T-Cell Lymphoma-Associated Hemophagocytic Syndrome Li, Na Jiang, Ming Wu, Wan-Chun Wei, Wen-Wen Zou, Li-Qun Front Oncol Oncology Nasal-type, extranodal nature killer (NK)/T-cell lymphoma-associated hemophagocytic syndrome (NK/T-LAHS) is a rare and life-threatening disease, requiring investigation of risk stratification. We conducted a retrospective study and proposed nomograms to predict NK/T-LAHS. The discriminative ability and calibration of the nomograms for prediction were tested using C statistics and calibration plots. We analyzed 533 patients with extranodal NK/T-cell lymphoma (ENKTL), out of which 71 were diagnosed with hemophagocytic syndrome (HPS), with a cumulative incidence of 13.3%. Significant difference for 2-year survival was found between patients with and without HPS (14.7% vs. 77.5%). Analyses showed that Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≥2, B symptoms, and bone marrow (BM) invasion were significantly associated with NK/T-LAHS. We used these data as the basis to establish a nomogram of risk index for ENKTL (RINK). In 335 patients with available data for Epstein-Barr virus DNA (EBV-DNA), we found high viral copies (≥4,450 copies/ml) were correlated with NK/T-LAHS. When these data were added to RINK, we developed another nomogram that included EBV-DNA data (RINK-E). The nomograms displayed good accuracy in predicting NK/T-LAHS with a C-statistics of 0.919 for RINK and a C-statistics of 0.946 for RINK-E, respectively. The calibration chart also showed an excellent consistency between the predicted and observed probabilities. The proposed nomograms provided individualized risk estimate of HPS in patients with ENKTL. Frontiers Media S.A. 2021-08-18 /pmc/articles/PMC8416502/ /pubmed/34490105 http://dx.doi.org/10.3389/fonc.2021.704962 Text en Copyright © 2021 Li, Jiang, Wu, Wei and Zou https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Li, Na
Jiang, Ming
Wu, Wan-Chun
Wei, Wen-Wen
Zou, Li-Qun
How to Identify Patients at High Risk of Developing Nasal-Type, Extranodal Nature Killer/T-Cell Lymphoma-Associated Hemophagocytic Syndrome
title How to Identify Patients at High Risk of Developing Nasal-Type, Extranodal Nature Killer/T-Cell Lymphoma-Associated Hemophagocytic Syndrome
title_full How to Identify Patients at High Risk of Developing Nasal-Type, Extranodal Nature Killer/T-Cell Lymphoma-Associated Hemophagocytic Syndrome
title_fullStr How to Identify Patients at High Risk of Developing Nasal-Type, Extranodal Nature Killer/T-Cell Lymphoma-Associated Hemophagocytic Syndrome
title_full_unstemmed How to Identify Patients at High Risk of Developing Nasal-Type, Extranodal Nature Killer/T-Cell Lymphoma-Associated Hemophagocytic Syndrome
title_short How to Identify Patients at High Risk of Developing Nasal-Type, Extranodal Nature Killer/T-Cell Lymphoma-Associated Hemophagocytic Syndrome
title_sort how to identify patients at high risk of developing nasal-type, extranodal nature killer/t-cell lymphoma-associated hemophagocytic syndrome
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8416502/
https://www.ncbi.nlm.nih.gov/pubmed/34490105
http://dx.doi.org/10.3389/fonc.2021.704962
work_keys_str_mv AT lina howtoidentifypatientsathighriskofdevelopingnasaltypeextranodalnaturekillertcelllymphomaassociatedhemophagocyticsyndrome
AT jiangming howtoidentifypatientsathighriskofdevelopingnasaltypeextranodalnaturekillertcelllymphomaassociatedhemophagocyticsyndrome
AT wuwanchun howtoidentifypatientsathighriskofdevelopingnasaltypeextranodalnaturekillertcelllymphomaassociatedhemophagocyticsyndrome
AT weiwenwen howtoidentifypatientsathighriskofdevelopingnasaltypeextranodalnaturekillertcelllymphomaassociatedhemophagocyticsyndrome
AT zouliqun howtoidentifypatientsathighriskofdevelopingnasaltypeextranodalnaturekillertcelllymphomaassociatedhemophagocyticsyndrome